New stocks and HK stocks are all in the red 😇
HSI Settles Lower by 640 pts as Financials Blown; HSBC HOLDINGS Slips 5% Below HKD150
China Life Insurance Company Limited, together with its subsidiaries, operates as a life insurance company in the People’s Republic of China. The company operat...
China Life declined 0.26% today, extending last week's -6.54% downtrend, primarily driven by Q3 earnings losses. The company reported Q3 earnings per share of negative HKD 1.86, a 138% year-over-year decline; Citi attributed the net profit decline to weak investment performance. The stock rose to HKD 23.44 in the morning session before retreating to HKD 23.10 at close. Though JPM and Morgan Stanley maintained overweight ratings post-earnings, market reaction to the losses weighed on the stock. Currently trading just 3.87% above its 52-week low and down 36.12% from the 52-week high, the stock shows a year-to-date decline of 19.9% and trades below its 60-day moving average of HKD 26.99. At a P/E of 7.4x and dividend yield of 4.88%, the valuation remains at historically low levels, while the insurance sector's Q3 solvency remained stable and UBS sustained a positive outlook on FYRP agent sales growth.
China Life declined 2.85% today, primarily hit by Q3 earnings disappointment. The insurer posted a net loss of RMB45.1 billion in Q3 2026, with EPS turning negative at -1.86 HKD; 1-9M cumulative net profit fell 46.7% year-over-year to RMB89.43 billion. The stock dipped to an intraday low of 22.92 HKD in afternoon trading before recovering slightly to close at 23.16 HKD. Despite the earnings miss, several major brokers maintained constructive stances following the results: JPM kept its Overweight rating, Morgan Stanley noted Q4 earnings were broadly in line with expectations, and BofA attributed profit volatility chiefly to investment headwinds; UBS further expects positive growth from the company's agent channel during the upcoming 'Good Start' campaign. From a valuation perspective, China Life is trading at deeply depressed levels: P/E of just 7.42, P/B of 0.86 (trading below book), and dividend yield of 4.87%, down over 35% from its 52-week high of 36.16 HKD—now near the 52-week low of 22.24 HKD—yet near-term investment challenges continue to weigh on sentiment.
China Life slipped 2.2% today, primarily dragged by a Q3 earnings bombshell—the insurer swung to a net loss of HKD 52.7 billion, plummeting 138% year-over-year and catching the market off guard. Intraday, the stock opened at 24.12 at 09:30, briefly touching a high of 24.16 by 09:40, but deteriorated throughout the afternoon session, sliding to a low of 23.74 by 15:59 before closing at 23.84. Despite near-term headwinds, both JPMorgan and UBS maintained constructive outlooks—JPM highlighted stable solvency metrics across China's insurance sector, while UBS expects the company's agent force to deliver positive growth during the ongoing 'Good Start' campaign. From a valuation perspective, the stock has fallen 17.34% year-to-date and now trades near its 52-week low of 22.24; with a P/E of 7.64 and P/B of 0.89, it remains compressed on multiples. The market appears to be balancing near-term earnings deterioration against longer-term value recovery.
China Life closed down 0.57% at HKD 24.38 today, displaying a V-shaped intraday pattern. Morning weakness, with the stock falling to a low of HKD 23.88, was primarily driven by the magnitude of Q3 earnings collapse—the company posted a net loss of approximately HKD 52.7 billion, a 46.7% YoY decline, with EPS turning sharply negative at -1.86 HKD. The afternoon bounce back to HKD 24.38 was supported by institutional reassurance: JPMorgan and Morgan Stanley maintain overweight ratings, attributing the loss mainly to investment-side volatility rather than fundamental deterioration, while Citi notes the company's 9-month NBV still leads peers. UBS recently reiterated optimism on agent business momentum under the 'Good Start' campaign. Valuation-wise, the stock remains depressed, down 15.46% year-to-date and 32.58% below the 52-week high of HKD 36.16, with a trailing PE of just 7.81 and PB ratio of 0.91, suggesting relative undervaluation. Yet continued pressure from investment performance warrants careful observation going forward.
China Life closed at HK$24.78, down approximately 2.36% for the day, pressured by a significant Q3 earnings swing to a loss. The company reported a net loss of HK$52.7 billion in Q3 (down 138% YoY), a sharp reversal from Q2's profit of HK$132.8 billion, with EPS falling from HK$4.70 to -HK$1.86. While major brokers including Morgan Stanley and Citi maintain an overweight rating and note the company's new business value remains peers-leading, investment volatility has become the primary headwind for profitability. On price positioning, the stock has declined 31.47% from its 52-week high of HK$36.16 and is down 14.08% year-to-date, trading above the 20-day moving average at HK$24.36 but below the 60-day average at HK$27.26, indicating a continued downtrend in the medium term. The market is digesting unfavorable earnings while entering a profit-taking phase.
Weekly Recap | CHINA LIFE -6.54%, underperforming the index
UBS Expects CHINA LIFE Agent FYRP to Post Positive Growth During "Good Start" Campaign; High-dividend Stock Allocation in Line with Target
Weekly Recap | CHINA LIFE +1.53%, most brokers rate it buy
A-Share Three Major Indices Open 2.1% to Nearly 5% Lower; Chip Stocks Slump, ZHONGJI INNOLIGHT Plunges 12%
Tiantu-backed Xige Shengke closes first tranche of Series A+ funding
JPM: China's Insurance Sector 3Q Solvency Largely Stable; Top Picks PING AN and CHINA LIFE
New stocks and HK stocks are all in the red 😇
HSI Settles Lower by 640 pts as Financials Blown; HSBC HOLDINGS Slips 5% Below HKD150
Hong Kong stocks are in a sea of red, dizzying 😵
HSI Settles Lower by 640 pts as Financials Blown; HSBC HOLDINGS Slips 5% Below HKD150
$ICBC(01398.HK)$CHINA LIFE(02628.HK)
🇨🇳 China Unleashes ¥360B Boost - What It Means for HK Markets 🇭🇰
China is pumping a massive ¥360 billion (~US$53.6 billion) to recapitalise eight top state-owned banks and insurers including ICBC, AgBank, and China Life.
Here’s the breakdown:
🏦 Stronger Financials
Replenishing Tier 1 capital for these heavyweight dual-listed H-shares eases margin pressure, stabilises valuations and secures those important dividend payouts.
📈 Institutional Support
With thicker capital buffers, state insurers can step in as market stabilizers. Look for them to deploy long-term funds into undervalued HK blue chips, lifting broader sentiment.
🛡️ Safer Macro Outlook
This backstop keeps credit flowing even amid soft domestic demand, directly tackling systemic risks.
A fortified banking system should help revive foreign investor confidence and bring capital back to Chinese assets.
👉 See the infographic for full details and market impact projections.
